KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.55 USD
-0.18 (-2.67%)
Updated May 17, 2024 03:57 PM ET
After-Market: $7.00 +0.45 (6.87%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth F Momentum D VGM
Brokerage Reports
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 21 - 40 ( 365 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
IND Application for KPI-012 in PCED Submitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Financial Results Reported; Reiterate Buy; Instituting $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Focus Remains on KPI-012/PCED, Ph2/3 Initiation in Q4:22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Financial Results Reported; Reiterate Buy; Adjusting PT to $2.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Pivoting the Pipeline to Focus on MSC-S; Takeaways from Wedbush Conference
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Sale of Commercial Products to Alcon Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
EYSUVIS and INVELTYS Sold to Alcon; Reiterate Buy; Modulating PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Win-Win: Kala Maximizes EYSUVIS & INVELTYS Value with Sale to Alcon
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS™ & EYSUVIS™
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Financial Results Reported; Reiterate Buy; Modulating PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q1: EYSUVIS Turns Into a "Show Me" Story with Expanded Coverage in Hand
Provider: Wedbush Securities Inc.
Analyst: AROUNIAN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: Wedbush Securities Inc.
Analyst: AROUNIAN Y